High Prevalence of Hepatitis C Virus Infection in One Dialysis Center in Bulgaria

Todorov, V; Boneva, Roumiana S.; Ilieva, P.; Doichinova, Tzetza; Donchev, Miroslav

doi:10.1159/000045031

Cited by 14 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6][7][8][9][10][11][12][13][14] Recent studies have shown that HCV is an important cause of morbidity and mortality in chronic dialysis patients. [15][16][17][18][19] Interferon-based therapy is the mainstay of therapy for HCV-related liver disease.…”

Section: Introductionmentioning

confidence: 99%

Meta‐analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

Fabrizi

Dulai²,

Dixit

et al. 2003

Aliment Pharmacol Ther

145

129

View full text Add to dashboard Cite

SUMMARYBackground: The efficacy of interferon monotherapy in dialysis patients with chronic hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue. Methods and aims: We evaluated the efficacy and safety of initial interferon monotherapy in dialysis patients with chronic hepatitis C by performing a systematic review of the literature with a meta-analysis of clinical trials. The primary outcome was sustained virological response (as a measure of efficacy); the secondary outcome was drop-out rate (as a measure of tolerability). We used the random effects model of Der Simonian and Laird, with heterogeneity and sensitivity analyses. Results: We have identified 14 clinical trials (269 unique patients); two were controlled studies. The mean overall estimate for sustained virological response (SVR) and drop-out rate was 37% [95% confidence interval (CI) 28-48] and 17% (95% CI 10-28),

show abstract

Section: Introductionmentioning

confidence: 99%

Meta‐analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

Fabrizi

Dulai²,

Dixit

et al. 2003

Aliment Pharmacol Ther

145

129

View full text Add to dashboard Cite

show abstract

“…In the dialysis centres of Romania and of other former communist countries, infections with hepatitic viruses have been poorly investigated. The few existing studies suggest that these infections are more frequent in patients dialysed in East European countries than elsewhere [6,7].…”

Section: Introductionmentioning

confidence: 99%

Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map?

Vladutiu

Cosa

Neamtu³

et al. 2000

Journal of Viral Hepatitis

View full text Add to dashboard Cite

We studied prospectively, between 1993 and 1998, the prevalence and incidence of markers against hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV), in 180 patients with chronic renal failure, dialysed in the Nephrological Clinic, Cluj. HBV and HCV markers were common in the patients who were already on haemodialysis in 1993 (antibodies to hepatitis B core antigen [HBcAb]: 57.9-88%; hepatitis B surface antigen [HBsAg]: 8.7-25%; antibodies to HCV [anti-HCV]: 73.7-100%; simultaneous occurrence of HBsAg and anti-HCV antibodies: 4.4-21%). These patients had the longest mean duration of haemodialysis therapy (6.79 +/- 4.82 years). The lowest prevalence was found in 1996, in the groups of patients included in the haemodialysis programme between 1993 and 1996 (HBcAb: 2.2-3.3%; HBsAg: 0-2.2%; anti-HCV antibodies: 0-2.2%; HBsAg and anti-HCV antibodies: 0-2.2%). The patients included since 1996 had, again, a high prevalence of markers (HBsAg: 21.6%; anti-HCV antibodies: 28.6%), despite the short duration of dialysis therapy (1.65 +/- 1.18 years). The incidence of infection was high before 1993, fell markedly between 1993 and 1996 (zero for the HBsAg and 6. 67% year-1 for the anti-HCV antibodies) and rose sharply between 1996 and 1998 (10.2%, respectively 29% year-1). The prevalence of HBV and HCV infections did not correlate with the age of the patients and depended, but only up to 1993, on the quantity of transfused blood. The link between the duration of the haemodialysis and the prevalence of the HBV and/or HCV infection proved nosocomial transmission. The very high prevalence and incidence of HBV and HCV infections, surpassing not only Western countries, but even those of 'developing' countries that are endemic for these infections, is characteristic of some former communist countries. A radical reform of the medical system in these countries is required.

show abstract

“…Table 4 demonstrates that the overall prevalence of anti-HCV among HD patients was almost one half (49.9%) according to clinical measurements and questionnaires. Prevalence of HBV and HCV in HD patients were reported by several authors ranging between 0.9% to 21.6% for HBV [62,63] and 3.4% to 65.8% for HCV. [64][65][66] There is a wide range in prevalence rates of HCV infection among HD patients in different regions of the world, ranging from 1% in the UK to more than 90% in Eastern Europe.…”

Section: Resultsmentioning

confidence: 98%

Hepatitis C Virus Antibodies Among Hemodialysis Patients in Makkah City, Kingdom of Saudi Arabia

Al-Khattabi¹

2019

ijsr

View full text Add to dashboard Cite

BACKGROUND: Hepatitis C virus (HCV) infection is the most common cause of chronic liver disease in the world and evaluation of the epidemiology of HCV infection was made possible by the development of a serological assay to detect antibodies to epitopes of HCV. Hemodialysis (HD) is considered to be one of the main risk factors of HCV transmission. The prevalence of antibodies to HCV (anti-HCV) in patients undergoing maintenance dialysis therapy (MDT) was found to be one of the highest among different risk groups and there is wide variation in the prevalence of HCV infection among different dialysis units and countries. Therefore, the prevalence of anti-HCV was studied in patients undergoing MDT. MATERIALS AND METHODS:The current study is a cross section one, where a sample of 361 HD patients were selected randomly from HD centers in three governmental hospitals in Makkah city and they were subjected to assessment for the prevalence of anti-HCV by using questionnaires in addition to clinical measurements. RESULTS:. The overall prevalence of anti-HCV among HD patients was 49.9% according to clinical measurements and questionnaire CONCLUSION: The overall prevalence of anti-HCV among HD patients in Makkah city (49.9%) was comparable to that reported from other parts of the Kingdom of Saudi Arabia (KSA) and it is almost similar to the already reported positivity rate of (43.2%) from t eastern region of KSA [1] and southern regions of KSA (45.5%). [2, 3] However, Strict adherence to universal precautions as recommended by the Center for Diseases Control (CDC), meticulous regular disinfection of HD machines, Strict isolation of HCV-positive patients, dedicated dialysis machines and nursing staff at new dialysis set-up could possibly be the reasons of relatively low anti-HCV positivity at the current study than that reported by Shaheen, et al [3,4] , from four centers in the western region of KSA, (72.3%) and that by Huraib, et al [5] [6] in their multi-center study in KSA, (68%) as well as the mean national rate. [3,7] On the other hand, the use of more sensitive third generation enzyme -linked immunosorbent assay (ELISA) technique, long duration on HD, multiple blood transfusions, patients with dialysis treatment in multi-centers, factors related to infrastructure, environment and operational system might be responsible for the high prevalence of anti-HCV found in this study than that reported earlier by Saeed, et al [8] from Riyadh and those observed in the central region of KSA.[9]Although routes of transmission are still unclear, early detection of all infected patients is mandatory for HCV prophylaxis in HD patients. Furthermore, an intensive educational program for staff members, HD patients and proper evaluation of the HD situation are needed. Thus, observation of appropriate preventive measures by all HDcenters is paramount.

show abstract

High Prevalence of Hepatitis C Virus Infection in One Dialysis Center in Bulgaria

Cited by 14 publications

References 10 publications

Meta‐analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

Meta‐analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map?

Hepatitis C Virus Antibodies Among Hemodialysis Patients in Makkah City, Kingdom of Saudi Arabia

Contact Info

Product

Resources

About